Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 9Carcinoma, Non-Small-Cell Lung 8Esophageal Squamous Cell Carcinoma 7Stomach Neoplasms 4Recurrence 4Neoplasm Metastasis 4Head and Neck Neoplasms 4Lung Neoplasms 3Colorectal Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Esophageal Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1NSCLC 1Multiple Pulmonary Nodules 1Mid-low Rectal Cancer 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1

Interventions

parsaclisib 2MLN 8237 2zanidatamab 1tislelizumab 1tanespimycin 1spartalizumab 1sitravatinib 1pembrolizumab 1pamiparib 1liposomal doxorubicin 1lenvatinib 1epothilone B 1cabiralizumab 1Temozolomide 1Nivolumab 1N-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride 1HMPL-013 1Capecitabine 1AZD7648 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Malignancies × tislelizumab × Clear all
NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Completed
404 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡